Albany, NY -- (SBWIRE) -- 11/13/2018 -- A recent report by ResearchMoz.us, titled, "Antipsychotic Drugs: Technologies and Global Markets," discusses the scope of the product. To do so, it throws light on the various factors pushing up its demand and those serving to restrain it. It also presents a detailed description of the competitive landscape, the pipeline, the regulations guiding the product development and launch, and the technological advancements. Besides, it gathers current and historical figures to understand the current and future market size.
The report states that the antipsychotic drugs is one of the biggest classes of pharmaceutical drugs seeing steady sales growth all over the world, and particularly in the U.S. At the forefront of driving demand in the antipsychotic drugs is the rising occurrence of psychosis and associated diseases. This is mainly because of the rising disorders such as substance-induced psychoses, genetic mutations, and physical illness owing to depression.
Apart from that, the global antipsychotic drugs market is also being boosted by the launch of newer types of antipsychotic compounds. This is mainly because of the substantial investments in research and development by players to expand their therapeutic applications of such medicines. All these initiatives will most likely diversify the antipsychotics portfolio in the years to come.
Get a Sample PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1911234
The global antipsychotic drugs market saw some dynamic changes between 2011 and 2016. Patent expiration for prominent blockbuster drugs around the time paved way for low-cost generic drugs. During the same time, a good number of novel formulations of antipsychotic drugs also made their way to the market thus disrupting its course. This was result of new approaches being tried by pharmaceutical companies for treating psychosisrelated indications. Those with unique action mechanisms and better delivery systems emerged as viable new alternatives for the existing antipsychotic drugs.
Having thrown light on the growth drivers, restraints, and trends shaping the trajectory of the global antipsychotic drugs market, the report goes on to segment it based on different parameters. Depending upon the mechanism of action for example it segments the market into D2/5HT2A, D2 partial agonists, and D2 antagonists. The market is comprised of both generic and branded drugs at the moment.
Depending upon disease indication, the report classifies the global antipsychotic drugs market into bipolar disorder, schizophrenia, major depressive disorder (MDD), and others. The others segment includes autism, anxiety, and dementia. Geographically, the report finds that currently North America rakes in most of the revenue in the market. Meanwhile, Asia Pacific is seeing highest growth at the moment.
Some of the prominent participants in the global antipsychotic drugs market are Acadia Pharmaceuticals, Inc., Alembic Pharmaceuticals Ltd., Alexza Pharmaceuticals, and Alkermes Plc. The report sheds light on their product offerings, including pipeline products and sales and revenues. It also attempts to understand the opportunities and pitfalls they are likely to encounter in the near term.